PDE5 inhibitor efficacy is estrogen dependent in female heart disease-Reference-Cited by-同舟云学术

PDE5 inhibitor efficacy is estrogen dependent in female heart disease

Published:2014-05-16 Issue:6 Volume:124 Page:2464-2471
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Sasaki Hideyuki,Nagayama Takahiro,Blanton Robert M.,Seo Kinya,Zhang Manling,Zhu Guangshuo,Lee Dong I.,Bedja Djahida,Hsu Steven,Tsukamoto Osamu,Takashima Seiji,Kitakaze Masafumi,Mendelsohn Michael E.,Karas Richard H.,Kass David A.,Takimoto Eiki

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference51 articles.

1. Therapeutic implications of the gender-specific aspects of cardiovascular disease

2. Heart Failure in Women

3. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update

4. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

5. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphodiesterases in heart and vessels- From Physiology to Diseases;Physiological Reviews;2023-11-16

2. Targeting estrogen receptor signaling for treating heart failure;Heart Failure Reviews;2023-10-03

3. Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry;Respiratory Research;2023-09-15

4. Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives;Pharmaceuticals;2023-09-06

5. The emerging role of estrogen's non-nuclear signaling in the cardiovascular disease;Frontiers in Cardiovascular Medicine;2023-04-12